Clinical trial imaging market seen reaching $2.36 billion by 2030
The clinical trial imaging market is forecast to grow from $1.58 billion in 2025 to $2.36 billion by 2030 as drug developers lean more on imaging data for trials, monitoring and regulatory requirements. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.
Why it matters: - Clinical trial imaging is becoming more central to drug development because it helps track disease progression, measure treatment effects and monitor participant safety. - The market’s growth reflects broader shifts in clinical research toward more complex protocols, precision medicine and data-rich trial designs. - The rising burden of chronic disease is increasing demand for imaging tools that can support better monitoring and analysis in trials.
What happened: - The Business Research Company said the clinical trial imaging market is projected to rise from $1.58 billion in 2025 to $1.72 billion in 2026. - The report forecasts the market will reach $2.36 billion by 2030. - The company said the market is expanding because of greater use of imaging endpoints in oncology studies, more global clinical trial activity, stricter regulatory expectations and advances in imaging technology. - The report also points to rising adoption of decentralized clinical trials, AI-powered imaging platforms, real-time imaging analytics and tighter integration with clinical platforms as growth drivers through 2030. - The company published a sample version of the report here.
The details: - Clinical trial imaging uses MRI, CT scans and X-rays to generate internal images of trial participants. - Those images help researchers evaluate therapies and assess safety during trials. - The report says the market is growing at a 9.3% compound annual growth rate from 2025 to 2026. - It projects an 8.2% CAGR through 2030. - The report says chronic diseases are a major demand driver because they require ongoing monitoring and are rising worldwide. - The report cites NCBI data from January 2023 showing that the number of people age 50 and older with at least one chronic disease is projected to nearly double from 71.522 million in 2020 to 142.66 million by 2050. - North America held the largest share of the market in 2025. - Asia-Pacific is expected to be the fastest-growing region over the next several years. - The regional analysis also covers Southeast Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The full report is available here.
Between the lines: - The forecast suggests clinical trial imaging is shifting from a supporting tool to a core research input as studies become more data-intensive. - AI and real-time analytics are likely to matter most where sponsors want faster readouts, tighter oversight and more efficient trial operations. - Regional growth outside North America points to a broader global expansion of clinical research infrastructure.
What's next: - The market’s next phase will likely be shaped by whether sponsors continue moving toward decentralized trial models and AI-enabled imaging workflows. - Demand will also depend on how quickly imaging platforms are integrated with broader clinical trial systems. - The company said its 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, hotspot infographics and updated graphics and tables.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Asia Business Gazette
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.